Focus: Eko Devices is a public-stage biotech company headquartered in Emeryville, CA, specializing in digital stethoscope technology for respiratory, cardiovascular, and nephrology indications. The company has pivoted from traditional drug development to medical device innovation with a clinical-evidence-driven approach.
Profile data last refreshed 7h ago · AI intelligence enriched 2w ago
Cooling — net -7 jobs in 30d
1 added, 8 removed. Slower than typical.
Best for commercial, enterprise, or product-focused professionals seeking medical device experience in a lean, public-stage organization; less suitable for bench scientists or those expecting large pipeline growth.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Multi-indication flagship device with evidence in pulmonary and hypertension management; core revenue driver for the company.
Help build intelligence for Eko Devices
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Eko Devices's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Second-generation device with broadest indication portfolio; multiple clinical trials demonstrate utility in structural and functional cardiac disease.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Deep Learning Algorithms to Detect Murmurs Associated With Structural Heart Disease.
Automated detection of low ejection fraction from a one-lead electrocardiogram: application of an AI algorithm to an electrocardiogram-enabled Digital Stethoscope().
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo